Oral hypoglycemic drugs: Pathophysiological basis of their mechanism of action

Citations of this article
Mendeley users who have this article in their library.


Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) include diet and exercise as first-line therapy plus hypoglycemic drugs. Actually there are seven distinct classes of anti-hyperglicemic agents, each of them displaying unique pharmacologic properties. The aim of this review is to describe the pathophysiological basis of their mechanism of action, a necessary step to individualize treatment of diabetic people, taking into proper consideration potential benefits and secondary effects of drugs.




Lorenzati, B., Zucco, C., Miglietta, S., Lamberti, F., & Bruno, G. (2010). Oral hypoglycemic drugs: Pathophysiological basis of their mechanism of action. Pharmaceuticals. https://doi.org/10.3390/ph3093005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free